Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities:
Net (loss) income	$ (26,525)	$ 44,588
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,907	5,480
Acquired in-process research & development	115,490
Bad debt recoveries	(59)	(277)
Stock-based compensation	12,608	9,298
Write-down of inventory and other	3,508	1,717
Accretion on marketable securities	918	94
Change in fair value of other investments	(17,648)	(23,823)
Gain on previously held interest in preCARDIA	(20,980)
Deferred tax provision	6,299	12,946
Change in fair value of contingent consideration	871	801
Other non-cash operating activities	751	970
Changes in assets and liabilities:
Accounts receivable	8,763	3,014
Inventories	(5,770)	(211)
Prepaid expenses and other assets	(8,697)	485
Accounts payable	(4,762)	(4,458)
Accrued expenses and other liabilities	(16,037)	(19,584)
Deferred revenue	(278)	719
Net cash provided by operating activities	55,359	31,759
Investing activities:
Purchases of marketable securities	(139,021)	(62,066)
Proceeds from the sale and maturity of marketable securities and other	123,823	139,813
Purchases of other investments and intangible assets	(3,866)	(2,000)
Purchases of property and equipment	(7,170)	(10,044)
Net cash (used for) provided by investing activities	(109,055)	13,756
Financing activities:
Proceeds from the exercise of stock options	2,120	1,010
Taxes paid related to net share settlement upon vesting of stock awards	(9,590)	(9,857)
Repurchase of common stock		(11,310)
Net cash used for financing activities	(7,470)	(20,157)
Effect of exchange rate changes on cash and cash equivalents	3,910	(2,872)
Net (decrease) increase in cash and cash equivalents	(57,256)	22,486
Cash and cash equivalents at beginning of period	232,710	192,341
Cash and cash equivalents at end of period	175,454	214,827
Supplemental disclosure of cash flow information:
Cash paid for income taxes	14,998	2,831
Supplemental disclosure of non-cash activities:
Contingent consideration related to the acquisition of Breethe		13,900
Property and equipment in accounts payable and accrued expenses	1,014	2,044
Right-of-use assets obtained in exchange for lease liabilities	283	804
Precardia
Investing activities:
Payments for acquisition	$ (82,821)
Breethe
Investing activities:
Payments for acquisition		$ (51,947)